Greater Cannabis Company, Inc.
Greater Cannabis Company, Inc. (GCAN): 2 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.0 months
D/E -1.00 · 0% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for Greater Cannabis Company, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$184K
Cash
$1K
Quarterly Burn
$4K
Runway
1.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| etp | Preclinical |
| novel cannabinoid therapeutic | Preclinical |
Frequently asked questions
How many drug candidates are in Greater Cannabis Company, Inc.'s pipeline?
Greater Cannabis Company, Inc. (GCAN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Greater Cannabis Company, Inc.'s lead drug candidate?
Greater Cannabis Company, Inc.'s most advanced tracked candidate is etp (Preclinical) for medical medicinal or recreational cannabis.
What is Greater Cannabis Company, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Greater Cannabis Company, Inc. has approximately 1.0 months of cash runway.
What is Greater Cannabis Company, Inc.'s market capitalization?
Greater Cannabis Company, Inc.'s market capitalization is approximately $184K.
Who is the CEO of Greater Cannabis Company, Inc.?
Mr. Aitan Zacharin is the chief executive officer of Greater Cannabis Company, Inc. (GCAN).
Get the full picture on Greater Cannabis Company, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.